These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27100303)

  • 41. Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX.
    Valentino LA; Cooper DL; Goldstein B
    Haemophilia; 2011 Jul; 17(4):579-89. PubMed ID: 21294815
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial.
    de Paula EV; Kavakli K; Mahlangu J; Ayob Y; Lentz SR; Morfini M; Nemes L; Šalek SZ; Shima M; Windyga J; Ehrenforth S; Chuansumrit A;
    J Thromb Haemost; 2012 Jan; 10(1):81-9. PubMed ID: 22470921
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors.
    Šalek SZ; Auerswald G; Benson G; Dolan G; Duffy A; Hermans C; Jiménez-Yuste V; Ljung R; Morfini M; Santagostino E; Lambert T
    Blood Transfus; 2017 Jan; 15(1):77-84. PubMed ID: 26674816
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor.
    Steen Carlsson K; Astermark J; Donfield S; Berntorp E
    Thromb Haemost; 2008 Jun; 99(6):1060-7. PubMed ID: 18521509
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Single higher dose of recombinant activated factor VII in the treatment of hemorrhages in patients with hemophilia complicated by inhibitors.
    Łaguna P; Mital A
    Adv Clin Exp Med; 2012; 21(4):519-24. PubMed ID: 23240458
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors.
    Young G; McDaniel M; Nugent DJ
    Haemophilia; 2005 May; 11(3):203-7. PubMed ID: 15876264
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Articular Bleeding in Hemophilia.
    Rodriguez-Merchan EC
    Cardiovasc Hematol Disord Drug Targets; 2016; 16(1):21-24. PubMed ID: 28049407
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature.
    Caviglia H; Candela M; Galatro G; Neme D; Moretti N; Bianco RP
    Haemophilia; 2011 Nov; 17(6):910-9. PubMed ID: 21342367
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
    Ballal RD; Botteman MF; Foley I; Stephens JM; Wilke CT; Joshi AV
    Curr Med Res Opin; 2008 Mar; 24(3):753-68. PubMed ID: 18234151
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors.
    Putnam KG; Bohn RL; Ewenstein BM; Winkelmayer WC; Avorn J
    Haemophilia; 2005 May; 11(3):261-9. PubMed ID: 15876272
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical and echographical control protocol of haemarthrosis in haemophilia patients with inhibitors: evaluation of the efficacy of recombinant factor VIIa in the evolution process (EFFISEVEN protocol).
    Querol F; Cortina V; Cid AR; Haya S; Aznar JA
    Haemophilia; 2008 Nov; 14 Suppl 6():36-44. PubMed ID: 19134032
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Methodologies for data collection in congenital haemophilia with inhibitors (CHwI): critical assessment of the literature and lessons learned from recombinant factor VIIa.
    Kessler CM; Benchikh El Fegoun S; Worster A
    Haemophilia; 2018 Jul; 24(4):536-547. PubMed ID: 29741299
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Elective surgery in patients with congenital coagulopathies and inhibitors: experience of the National Haemophilia Centre of Venezuela.
    Boadas A; Fernández-Palazzi F; De Bosch NB; Cedeño M; Ruiz-Sáez A
    Haemophilia; 2011 May; 17(3):422-7. PubMed ID: 21118333
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recombinant activated factor VII: 30 years of research and innovation.
    Hedner U
    Blood Rev; 2015 Jun; 29 Suppl 1():S4-8. PubMed ID: 26073368
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Experience with use of recombinant activated factor VII.
    Divanon F; Hecquard C; Borel-Derlon A
    J Clin Pharm Ther; 2002 Apr; 27(2):133-8. PubMed ID: 11975698
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Major orthopaedic surgeries for haemophilia with inhibitors using rFVIIa.
    Takedani H; Kawahara H; Kajiwara M
    Haemophilia; 2010 Mar; 16(2):290-5. PubMed ID: 19925628
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rapid rFVIIa enhanced on-demand dosing in haemophilia inhibitor patients.
    Morfini M
    Eur J Haematol; 2016 Feb; 96(2):111-8. PubMed ID: 26172449
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies.
    Holme PA; Brosstad F; Tjønnfjord GE
    Haemophilia; 2005 Sep; 11(5):510-5. PubMed ID: 16128896
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Overall experience with NovoSeven.
    Négrier C; Lienhart A
    Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S19-24. PubMed ID: 10850559
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recombinant activated factor VII as a universal haemostatic agent.
    Hedner U
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S147-52. PubMed ID: 9819047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.